Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 13, 2006

Enzo Acquires License to RNA Amplification Patents

  • Enzo Biochem received a license to a comprehensive non-PCR-based amplification technology that allows researchers to increase amplification from relatively small RNA samples in gene expression studies. This licence with LBS Technologies includes rights to six U.S. patents, which are all related to this technology.

    Unlike exponential amplification techniques, such as RT-PCR, linear amplification technology maintains the relative ratios of the starting RNA population, thereby allowing for more accurate expression profile studies. This technique involves a series of enzymatic reactions that produce a nonexponential amplification of RNA from relatively small amounts of RNA extracted from biopsies, laser-capture microdissection, and other tissue sources where the sample size is limited.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »